Advice
Following a full submission.
Pegylated interferon alfa 2a (Pegasys) is accepted for use within NHS Scotland for the treatment of HBeAg-positive or HBeAg-negative chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, increased ALT and histologically verified liver inflammation and/or fibrosis.
Compared with conventional interferon alfa 2a, it offers comparable efficacy and the convenience of once-weekly rather than three-times weekly subcutaneous administration. It has been shown to be cost-effective when compared to a number of comparator medicines in a range of patient groups.
Download detailed advice48KB (PDF)
Medicine details
- Medicine name:
- Pegylated interferon alfa 2a (Pegasys®)
- SMC ID:
- 186/05
- Indication:
- HBeAg-positive or HBeAg-negative chronic hepatitis B
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 July 2005